GForce-PD News

Fantastic work coming from GForce-PD member Jun Takahashi and colleagues

posted in: Sidebar | 0

Reprogrammed cells relieve Parkinson’s symptoms in trials

Japanese researchers report promising results from an experimental therapy for Parkinson’s disease that involves implanting neurons made from ‘reprogrammed’ stem cells into the brain. A trial conducted in monkeys with a version of the disease showed that the treatment improved their symptoms and seemed to be safe, according to a report published on 30 August in Nature.

Another way to dial back stem cell hype (but not hope): Put a dollar figure on it

posted in: Sidebar | 0

Another way to dial back stem cell hype (but not hope): Put a dollar figure on it

In an effort to reign in the hype surrounding stem cell research that has led to a proliferation of unapproved and potentially dangerous stem cell therapies, the International Society for Stem Cell Research (ISSCR) recently released updated guidelines outlining conduct for stem cell researchers that, for the first time, included communications activities.

Good to see responsible interpretation of the data

posted in: Sidebar | 0

StemCells, Inc. Announces Termination of Phase II Pathway Study Following Review of Data

NEWARK, Calif., May 31, 2016 (GLOBE NEWSWIRE) — StemCells, Inc. (NASDAQ: STEM) (the “Company”) today announced its decision to terminate the Company’s Phase II Pathway Study in spinal cord injury following an in-depth review of data from the study and after obtaining the concurrence of the study’s Interim Analysis Data Monitoring Committee (the “IA-DMC”).

National Stem Cell Foundation and Michael J. Fox Foundation Partner to Support Parkinson’s Cell Replacement Therapy

posted in: Sidebar | 0

National Stem Cell Foundation and Michael J. Fox Foundation Partner to Support Parkinson’s Cell Replacement Therapy

LOUISVILLE and NEW YORK, May 25, 2016 /PRNewswire-USNewswire/ — The National Stem Cell Foundation (NSCF) and The Michael J. Fox Foundation for Parkinson’s Research (MJFF) have announced a partnership to fund development of a cutting-edge therapy to replace the dopamine neurons that degenerate in Parkinson’s disease, the second most common brain disease after Alzheimer’s.

GForce-PD Facebook Feed

We look back to an exciting meeting of the GForce-PD group in kyoto. Strong progress from all groups. ...

View on Facebook